ISRCTN77942127 https://doi.org/10.1186/ISRCTN77942127

Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol

Submission date 08/09/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 27/10/2005	**Overall study status** Completed	
Last Edited 11/10/2016	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Matthew Walters

Contact details
Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
United Kingdom
G11 6NT
+44 (0)141 211 2821
gcl203@clinmed.gla.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title
Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol

Study objectives
To investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in hypertension.

Ethics approval required
Old ethics approval format

Ethics approval(s)
West Ethics Committee of NHS Greater Glasgow and Clyde, 18/12/2003, ref: 03/118 (1)

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied
Hypertension

Interventions
Patients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of acetazolamide after which MFV will be measured. MFV in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion. Patients then receive a supply of either losartan and atenolol tablets for 4 weeks after which they will undergo cardiovascular reactivity (CVR) assessment as before. A 1-week washout period of no medication will follow, then the protocol repeated with the alternated tablet.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Losartan, atenolol

Primary outcome measure
Changes in cerebrovascular reactivity.

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/08/2004

Completion date
01/02/2006

Eligibility

Key inclusion criteria
1. Male: 50-80 years
2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH)
3. Blood pressure (BP) 150-200/90-115

Participant type(s)
Patient

Age group
Adult

Sex
Male

Target number of participants
13

Key exclusion criteria
1. >70% internal carotid artery (ICA) stenosis
2. Middle cerebral artery (MCA) stenosis
3. Contra-indication to losartan, atenolol or acetazolamide
4. Serum creatinine >130 µmol/l
5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment

Date of first enrolment
01/08/2004

Date of final enrolment
01/02/2006

Locations

Countries of recruitment
Scotland

United Kingdom

Study participating centre
Western Infirmary
Glasgow
United Kingdom
G11 6NT

Sponsor information

Organisation
University of Glasgow (UK)

Sponsor details
University Avenue
Glasgow
Scotland
United Kingdom
G11 6NT
+44 (0)141 211 2176
pcn1w@clinmed.gla.ac.uk

Sponsor type
University/education

ROR
https://ror.org/00vtgdb53

Funder(s)

Funder type
University/education

Funder Name
University of Glasgow

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
Universities (academic only)

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration